Nasdaq GlobeNewswire

Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries

Del

NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which showed an overall increase of 9% in surgical and non-surgical cosmetic procedures within the past twelve months.

Ranking of the World's Top Ten Countries for Cosmetic Procedures
The top five countries - USA, Brazil, Japan, Italy and Mexico - account for 41.4% of the world's cosmetic procedures, followed by Russia, India, Turkey, Germany and France.

Ranking   Country: Total 
number of 
procedures  
% of World-Wide 
Total
1 USA  4,217,862  17.9 %
2 Brazil  2,524,115  10.7 %
3 Japan  1,137,976  4.8 %
4 Italy  957,814  4.1 %
5 Mexico  923,243  3.9 %
6 Russia  896,629  3.8 %
7 India  878,180  3.7 %
8 Turkey  789,564  3.3 %
9 Germany  730,437  3.1 %
10 France  517,731  2.2 %
11 Colombia  505,161  2.1 %
12 Spain  473,074  2.0 %
13 Chinese Taipei    387,815  1.6 %
14 Egypt  376,348  1.6 %
15 Greece  287,918  1.2 %
16 Argentina  272,420  1.2 %
17 Venezuela  244,552  1.0 %
18 Australia  225,002  1.0 %
19 Belgium  195,665  0.8 %
20 Iran  151,439  0.6 %
21 Thailand  112,821  0.5 %
22 Lebanon  79,769  0.3 %
23 Romania  76,911  0.3 %
24 South Africa  45,413  0.2 %
       

The Fastest Growing Cosmetic Procedures
In 2016, Labiaplasty showed the largest increase in number of procedures from 2015, with a 45% rise, followed by the Lower Body lift which increased by 29%, the Upper Body Lift and Breast Augmentation using Fat Transfer both demonstrating equal growth at 22%, and the Buttock Lift increasing by 20%.

The Most Popular Cosmetic Surgical Procedures
Breast Augmentation continued to be the world's most popular cosmetic procedure, accounting for 15.8% of all surgical procedures, followed by Liposuction (14%), Eyelid Surgery (12.9%), Rhinoplasty (7.6%) and Abdominoplasty (7.4%). The least popular cosmetic surgery in 2016 was penile enlargement, which also saw the largest decrease in number of procedures (-28%).

The most popular non-surgical procedures continue to be injectables with Botulinum Toxin ranking at number one at 4,627,752 procedures (a 7% increase over the past 12 months).

The Gender Difference
Women continue to drive the demand for cosmetic procedures, accounting for 86.2%, or 20,362,655 cosmetic procedures worldwide. The five most popular procedures requested by women are Breast Augmentation (Silicone Implant), Liposuction, Eyelid Surgery, Abdominoplasty and Breast Lift.

In 2016, men accounted for 13.8% of cosmetic patients with 3,264,254 procedures performed worldwide. Their top five cosmetic procedures requested by men are Eyelid Surgery, Gynecomastia, Rhinoplasty, Liposuction and Hair Transplant.

President of ISAPS, Dr. Renato Saltz, comments, "These results confirm something that most board-certified plastic surgeons already knew - that the demand for cosmetic procedures is stronger than ever. Around the world, we are seeing record numbers of patients looking to take advantage of the latest innovations in cosmetic surgery to look and feel better about themselves."

Survey Methodology
The data on aesthetic/cosmetic surgical and non-surgical procedures performed in 2016 was tabulated with a questionnaire sent to approximately 35,000 plastic surgeons in ISAPS' proprietary database. ISAPS is the only organization that collects this type of cosmetic data annually on a global scale. The results were compiled, tabulated and analyzed by Industry Insights, an independent research firm based in Columbus, Ohio. For a copy of full results, please visit www.ISAPS.org.

About ISAPS
The International Society of Aesthetic Plastic Surgery is the premier global organization for board-certified plastic surgeons. Regarded as the leading global authority on aesthetics and cosmetic surgery, ISAPS has over 3,200 members in 104 countries. Through its rigorous membership requirements, ISAPS plastic surgeons are considered to be among the most qualified in their respective countries, making it easy for patients who are considering cosmetic surgery to start their journey by meeting with an ISAPS plastic surgeon. A full list of ISAPS plastic surgeons can be found at www.ISAPS.org

Media Contact: 
Julie Guest, ISAPS Chief Marketing Officer 
marketing@ISAPS.org 
1-844-867-3621



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ISAPS via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

Early Warning Report23.5.2018 20:05Pressemelding

VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) announces that pursuant to a warrant exercise, it has acquired for a purchase price of C$803,571, direct ownership of 5,357,142 common shares (the "Shares") of Prospero Silver Corp. ("Prospero"), of 510 West Georgia Street, Suite 1800, Vancouver, BC V6B 0M3, at a price of C$0.15 per Share. Immediately following this transaction, Fortuna owned 10,714,284 common shares of Prospero, representing 22.74% of the issued and outstanding common shares of Prospero. Immediately prior to the transaction, Fortuna owned 5,357,142 common shares and 5,357,142 common share purchase warrants. The Shares were acquired by Fortuna for investment purposes, and depending on market and other conditions, it may from time to time in the future increase or decrease its ownership, control or direction over securities of Prospero through market transactions, private agreements, or otherwise. Fortuna has fil

GaN Systems to Showcase Innovative GaN Power Technologies and Customer Solutions at PCIM Europe 201823.5.2018 15:00Pressemelding

Record-setting GaN transistors and an array of new products, design tools, and reference designs that make it easier to develop ground-breaking power systems will be displayed OTTAWA, May 23, 2018 (GLOBE NEWSWIRE) -- GaN Systems, the global leader in GaN (gallium nitride) power semiconductors, today announced that it will be exhibiting the company's new products and design tools and presenting customer demonstrations at PCIM Europe 2018 (Power Conversion and Intelligent Motion), Booth 511 in Hall 9 (9-511) from June 5-6, 2018 in Nuremberg, Germany. At PCIM Europe, one of the leading exhibitions for power electronics and its applications, attendees to the GaN Systems booth will learn about new products, the numerous IC companies that have collaborated with GaN Systems, and a vast array of customer implementations spanning the consumer, data center, industrial, and automotive market segments. Also, GaN Systems' subject matter experts will be speaking at four sessions over the course of t

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom